U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07535034) titled 'A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants' on April 10.
Brief Summary: The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Gout
Intervention:
DRUG: Dotinurad
Over-encapsulated tablets containing active drug substance administered orally.
OTHER: Placebo
Capsules containing microcrystalline cellulose administered orally.
Recruitment Status:...